Perspective Therapeutics, Inc. short interest in 2018
In 2018, Perspective Therapeutics, Inc.'s disclosed short interest ran from 0.21% of shares outstanding on 12 Jan 2018 to 1.65% on 31 Dec 2018, a change of +1.44 percentage points. The year's high was 1.65% on 31 Dec 2018 and its low 0.07% on 15 Mar 2018, averaging 0.69% across 18 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.76 days on 30 Nov 2018. Full history: Perspective Therapeutics, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2018 in figures
- Start of year
- 0.21% (12 Jan 2018)
- End of year
- 1.65% (31 Dec 2018)
- Change
- +1.44 pp
- High
- 1.65% (31 Dec 2018)
- Low
- 0.07% (15 Mar 2018)
- Average
- 0.69%
- Highest days to cover
- 9.76 (30 Nov 2018)
- SEC filings marked
- 10
Every report in 2018
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2018 | 0.21% | 1.00 | |
| 31 Jan 2018 | 0.11% | 1.00 | results (8-K) |
| 15 Feb 2018 | 0.12% | 1.00 | results (8-K), 10-Q filed |
| 28 Feb 2018 | 0.10% | 1.00 | |
| 15 Mar 2018 | 0.07% | 1.00 | |
| 29 Mar 2018 | 0.10% | 1.00 | |
| 13 Apr 2018 | 0.11% | 1.00 | |
| 30 Apr 2018 | 0.09% | 1.00 | results (8-K) |
| 15 May 2018 | 0.28% | 1.00 | results (8-K), 10-Q filed |
| 31 May 2018 | 0.18% | 1.00 | |
| 29 Jun 2018 | 0.17% | 1.00 | |
| 28 Sep 2018 | 1.43% | 1.23 | results (8-K), 10-K filed |
| 15 Oct 2018 | 1.56% | 2.75 | |
| 31 Oct 2018 | 1.60% | 4.74 | |
| 15 Nov 2018 | 1.51% | 4.38 | results (8-K), 10-Q filed |
| 30 Nov 2018 | 1.58% | 9.76 | |
| 14 Dec 2018 | 1.52% | 9.46 | |
| 31 Dec 2018 | 1.65% | 3.93 |
See also: Perspective Therapeutics, Inc.'s full history · most shorted US stocks of 2018 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.